🔬 Latest pharma industry updates 👇

😮 Trump declares willingness to impose 25% tariffs on pharma starting in April.

🚫 FDA also cuts many device and food staff, rising concerns arround timelines and staff to review innovations.

❌ bluebird bio to be sold for less than $30M to Carlyle & SK, marking a subdued end to a once-pioneering gene therapy biotech.

🏳️‍🌈 U.S. pharma quietly pulls diversity references from their annual reports - BMS, J&J, and Biogen downplay or omit DEI commitments.

⚖️ Novo Nordisk sues KBP Biosciences claiming withheld trial data led to a failed $1.3B hypertension drug deal.

❌ Otsuka scraps several oncology programs for “strategic reasons,” trimming its cancer pipeline.

🦠 U.S. avian flu crisis intensifies with nearly 158M poultry culled over 3 years, raising pandemic fears.

🤝 Stilla Technologies acquired by Bio-Rad Laboratories for up to $275M.

💊 Eli Lilly and Company licenses OliX Pharmaceuticals, Inc.’s OLX75016 (RNA therapy) for MASH and related fibrosis, with up to $630M milestones.

🧩 Biogen pays $165M for rights to Stoke Therapeutics’s Dravet syndrome candidate zorevunersen (RNA therapy).

📊 Ireland’s trade surplus with the U.S. hits €50B, driven by a 44% jump in pharmaceutical and chemical exports.

💪 Solid Biosciences disclosed strong early Duchenne gene therapy data and raised $200M

🟢 GSK’s vaccine, Penmenvy, receives FDA approval for broad meningococcal protection in teens and young adults.

👵 Europe’s life expectancy rise slows, partly due to COVID-19, plateauing gains in cardiovascular and cancer outcomes.

🏭 Altitude Labs launches fund for biotech startups impacted by NIH budget cuts, offering $100k-$250k plus lab space.

🤝 Sanofi finalizes deal with CD&R for 50% stake in Opella.

💔 Supernus Pharmaceuticals, Inc.’ depression candidate SPN-820 disappoints in mid-stage trial; shares drop as it rethinks future with partner Navitor.

📈 BridgeBio’s ATTR-CM drug outperforms expectations, doubling prescription counts vs. Pfizer’s tafamidis.

😩 U.S. infant mortality rises in states restricting abortion; notably higher among Black infants and those with congenital issues.

😮 Eli Lilly and Company stocks nearly $550M worth of obesity med orforglipron pre-launch.

🙏 Functionally blind man in Ireland regains sight with Spark Therapeutics, Inc.’s Luxturna gene therapy.

📊 FDA ends semaglutide shortage; compounding pharmacies lose out as Novo Nordisk supply now meets U.S. demand.

🤝 Incyte teams with Genesis on AI-driven small molecule discovery, pays $30M upfront, up to $295M in milestones.

👁️ Concentra offers to buy ACELYRIN, INC., conflicting with previous proposed merger with Alumis.